A Novel Ferumoxytol-enhanced Cardiac Magnetic Resonance for the Detection of Calcified Coronary Arteries

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorThe First Affiliated Hospital with Nanjing Medical University

About this trial

This study is a single-center, prospective, controlled, diagnostic study. The study will be consecutive and is expected to enroll 100 patients with CCTA confirmed coronary calcified lesions. The purpose of this study was to compare the accuracy of novel Ferumoxytol-enhanced Cardiac Magnetic Resonance (Fe-CMR) and coronary CT angiography (CCTA) in detecting calcified coronary arteries, using coronary angiography (CAG) and optical coherence imaging (OCT) as gold standards.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥18 years, <75 years;

Imaging specialists evaluate CCTA images taken within 30 days and report that calcification occupied one or more of the patient's vascular lumen at an angle of >50% (using the coronary artery segmentation method recommended by the American Heart Association, including nine segments of the major branches of the coronary artery);

Patient who will undergo coronary angiography;

Patient with normal renal function or chronic renal insufficiency (CKD) stage 1-3;

Disqualifiers

People who are allergic to iodine contrast media or have a history of allergy to iron or dextran or are allergic themselves;

Because of psychological (such as suffering from claustrophobic syndrome) or physical reasons (such as the presence of metal objects in the body) can not receive MRI examination;

suffering from terminal diseases (such as malignant tumors) or life expectancy < 1 year;

Pregnant or lactating women;

Trial population

100 patients with CCTA proven calcified lesions occupying greater than 50% of the angle of the vascular lumen at the First Affiliated Hospital of Nanjing Medical University.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Superparamagnetic Iron Oxide Nanoparticles

    Drug

    Patients will receive a novel ferumoxytol-enhanced cardiac magnetic resonance imaging.

Treatment groups

100 Participants
are divided into 1 treatment group
Group A: patients with calcified lesions1 intervention

Trial outcomes

Primary outcomes

1

Degree of vascular stenosis at the site of coronary calcification.

Degree of vascular stenosis at the site of coronary calcification(measured by CAG, CCTA, Fe-CMRA): 0-100%.

Time frame
baseline

Secondary outcomes

1

CT-FFR, Agatston score, and the angle of calcification lesions occupying vascular lumen

①CT-FFR: computed tomography fractional flow reserve. ②Agatston score:0 point: No calcification; 1 to 10 points: Minimal plaque burden; 11 to 100 points: Mild plaque burden; 101 to 400 points: Moderate plaque burden; Greater than 400 points: Extensive plaque burden. ③the angle of calcification lesions occupying vascular lumen (CCTA):0°-360°

Time frame
baseline
2

calcium score of the plaque measured by OCT

OCT: calcium score of the plaque (①Calcification angle: the angle of the calcified plaque surrounding the vessel wall, a larger angle indicates more severe calcification. ②Calcification length: the longitudinal extension length of the calcified plaque along the vessel. ③Calcification thickness: the maximum thickness of the calcified plaque).

Time frame
baseline
3

Fe-CMRA image quality score

Fe-CMRA image quality score: the image quality was assessed by a 4-point scale: 1=poor (coronary vessel barely evident or noisy image); 2=moderate (coronary vessel visible but diagnostic confidence low); 3=good (coronary artery adequately visualized and diagnostic quality image); and 4=excellent (coronary artery clearly depicted).

Time frame
baseline

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

The First Affiliated Hospital with Nanjing Medical University

Lead sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Collaborator